ASX biotech stock Mesoblast Ltd (ASX: MSB) is under pressure on Thursday, down 5.4% to $2.10 in afternoon trade.
The pullback comes despite a solid quarterly update released before the market open. Mesoblast reported net revenues of US$30.3 million from its flagship Ryoncil® therapy and cut its net operating cash spend to just US$4.1 million.
Even so, the stock is now down around 22% year to date, compared to a marginal 0.3% decline for the S&P/ASX 200 Index (ASX: XJO).
So, what did the company actually report?
Image source: Getty Images
Ryoncil keeps gaining traction
Mesoblast is starting to build real commercial momentum.
Ryoncil® generated gross sales of US$35.3 million for the March quarter, translating into net revenues of US$30.3 million. That puts cumulative revenues since launch close to the US$100 million mark.
CEO Dr Silviu Itescu said:
We've had a busy and exciting March quarter marked by a series of major achievements. Ryoncil® revenues are now approaching US$100 million since last year's launch, we have substantially improved our net operating cash spend, our pivotal trial in inflammatory back pain has successfully achieved its patient recruitment target, and we have bolstered our long-term leadership in the field by acquiring genetically modified technology for precision-enhanced cell therapy products.
At the same time, the company sharply reduced its quarterly cash burn to US$4.1 million and finished the period with a healthy US$122 million in cash.
Pipeline progress building
Beyond sales, Mesoblast is advancing its broader pipeline.
The ASX biotech stock hit a key milestone in its phase 3 trial for chronic low back pain, successfully completing patient recruitment. That's a crucial step toward potential commercialisation.
It also secured US FDA clearance to begin registrational trials of Ryoncil® in new indications, including Duchenne muscular dystrophy and adult steroid-refractory acute graft versus host disease.
On the innovation front, Mesoblast used its inaugural R&D day to unveil a strategic acquisition, a patented CAR (chimeric antigen receptor) technology. This move aims to strengthen its position in next-generation cell therapies, particularly in autoimmune diseases like lupus and inflammatory bowel conditions.
What's next for the ASX stock?
With more than US$120 million in cash and access to funding, the ASX stock says it is well placed to expand Ryoncil® into additional indications and push ahead with new clinical trials.
The company is also targeting broader global opportunities, while continuing to invest in next-generation therapies built on its CAR platform.
So why the sell-off?
Despite the positive update, the share price reaction suggests expectations may have already been high.
After a strong run in previous periods – the ASX stock is still 17% up over 12 months – investors could be taking profits. Or they might be waiting for further proof that revenue growth can translate into sustained profitability.
